"Poseida Therapeutics' Allogeneic CAR-T Shows Promising Results in Multiple Myeloma Trial"
Poseida Therapeutics presented positive early results from its Phase 1 trial of P-BCMA-ALLO1, an allogeneic CAR-T therapy, in relapsed/refractory multiple myeloma (RRMM) at the 65th American Society of Hematology (ASH) Annual Meeting. The therapy demonstrated an 82% overall response rate (ORR) and deep clinical responses in heavily pretreated patients, with no graft-vs-host disease (GvHD) or dose-limiting toxicities observed. The therapy also showed promising persistence and differentiation of CAR-T cells, supporting the potential of allogeneic T stem cell memory (TSCM)-rich CAR-T therapies. Poseida Therapeutics plans to continue developing P-BCMA-ALLO1 in partnership with Roche.